DE102014206156A1 - Sunscreens with encapsulated UV filters III - Google Patents

Abstract

Cosmetic preparation containing a) a polymethyl methacrylate (PMMA) encapsulated UV filter and b) one or more perfumes.

Description

The present invention relates to a cosmetic preparation containing a polymethyl methacrylate (PMMA) encapsulated UV filter and perfumes.

The trend away from the noble paleness towards the "healthy, sporty brown skin" has been unbroken for years. To achieve this, people expose their skin to solar radiation, as it causes pigmentation in the sense of melanin formation. However, the ultraviolet radiation of sunlight also has a damaging effect on the skin. In addition to the acute injury (sunburn), long-term damage such as an increased risk of developing skin cancer occurs due to excessive exposure to light from the UVB range (wavelength: 280-320 nm). The excessive action of the UVB and UVA radiation (wavelength: 320-400 nm) also leads to a weakening of the elastic and collagen fibers of the connective tissue. This leads to numerous phototoxic and photoallergic reactions and leads to premature skin aging.

To protect the skin, therefore, a number of sunscreen filter substances have been developed which can be used in cosmetic preparations. These UVA and UVB filters are summarized in most industrialized countries in the form of positive lists such as Appendix 7 of the Cosmetics Regulation.

However, the variety of commercially available sunscreens must not obscure the fact that these prior art formulations have a number of disadvantages.

Cosmetic preparations, such as sunscreen preparations applied to the skin, regularly (intentionally or unintentionally) come into contact with garments and items of laundry (eg towels) on which they are (eg, "attrition" or "sucked" by the fibers). to adhere in part. In this way, depending on the nature of the ingredients, especially on bright textiles stains and discoloration. These discolorations are caused in particular by non-water-soluble UVA and broadband filters. The stains are difficult to remove by washing with conventional detergents and even increase during the washing process by interactions with ions of the wash water.

It was therefore the object of the present invention to eliminate the disadvantages of the prior art and a cosmetic preparation (in particular a sunscreen) containing non-water-soluble UVA filters, such as 4- (tert-butyl) -4'-methoxydibenzoylmethane and / or broadband filters such as, to develop bis-ethylhexyloxyphenol methoxyphenyl triazines, which are easier to wash out of textiles contaminated with the formulation.

Due to their polymer and UV filter content, cosmetic sunscreens usually have a certain stickiness, which, in particular when used on the beach, leads to the adhesion of sand to creamy areas of the skin. This problem becomes more pronounced the more UV filter a preparation contains. Although there has been no lack of attempts to develop sand-repellent sunscreens in the past, this problem has not yet been satisfactorily resolved, especially in preparations with a high sun protection factor.

It was therefore the object of the present invention to develop a sand-repellent sunscreen with low tackiness. In particular, a sunscreen with a high sun protection factor (SPF 50 and higher) should be developed, which is particularly low in sand adhesion.

In addition to the stickiness / sand adhesion, cosmetic sunscreens additionally have the problem that a large number of UV filters are not particularly soluble in the preparations. In particular, when formulations with high SPF and high UV filter content are developed, the solubility of triazine derivatives and 4- (tert-butyl) -4'-methoxydibenzoylmethane presents a problem for the developers.

It was therefore the object of the present invention to develop a sunscreen in which difficult to dissolve UV filters such as triazine derivatives and 4- (tert-butyl) -4'-methoxydibenzoylmethane can be incorporated in larger quantities.

Another disadvantage of the prior art is the fact that a number of other ingredients in sunscreen are photolabile and / or destroyed under thermal stress. The photolability of the UV-A filter and 4- (tert-butyl) -4'-methoxydibenzoylmethane is a particular challenge.

It was therefore the object of the present invention to develop a photostable preparation.

• a) einen mit Polymethylmethacrylat (PMMA) verkapselten UV-Filter und
• b) ein oder mehrere Parfümstoffe.

Surprisingly, the objects are achieved by containing a cosmetic preparation

• a) a polymethyl methacrylate (PMMA) encapsulated UV filter and
• b) one or more perfumes.

In particular, it was surprising that the stains resulting from the formulations according to the invention on textiles are easy to remove by washing with conventional detergents and that the preparations show drastically reduced sand adhesion / stickiness.

Although the expert knows the WO 2006/046803 A1 However, this document could not point the way to the present invention.

It is advantageous according to the invention, when encapsulated as encapsulated UV filter 4- (tert-butyl) -4'-methoxydibenzoylmethane (INCI butyl Methoxydibenzoylmethane) and / or encapsulated 2,4-bis - {[4- (2-ethyl-hexyloxy ) -2-hydroxy] -phenyl} -6- (4-methoxyphenyl) -1,3,5-triazine (INCI bis-ethylhexyloxyphenol methoxyphenyl triazines).

Moreover, it is advantageous according to the invention if the capsules of the PMMA-encapsulated UV filters have an average size of 0.1 to 15 μm. Encapsulated UV filters with this particle size can be incorporated into the preparations in a particularly stable manner.

According to the invention, it is preferred if the capsules of the PMMA-encapsulated UV filters have an average size of 1 to 10 μm.

If the preparation contains encapsulated 4- (tert-butyl) -4'-methoxydibenzoylmethane (INCI butyl methoxydibenzoylmethane), it is advantageous according to the invention if the preparation comprises encapsulated 4- (tert-butyl) -4'-methoxydibenzoylmethane (INCI butyl methoxydibenzoylmethane )) in an amount of 0.1 to 20% by weight, based on the total weight of the preparation. It is preferred according to the invention for the encapsulated 4- (tert-butyl) -4'-methoxydibenzoylmethane (INCI butyl methoxydibenzoylmethane)) to be present in an amount of from 1 to 20% by weight, based on the total weight of the preparation. These amounts are based on the total weight of butyl methoxydibenzoylmethane and PMMA.

If the preparation comprises encapsulated 4- (tert-butyl) -4'-methoxydibenzoylmethane (INCI butyl methoxydibenzoylmethane), it is advantageous according to the invention if the preparation comprises 4- (tert-butyl) -4'-methoxydibenzoylmethane (INCI butyl methoxydibenzoylmethane) in an amount of 0.1 to 5% by weight, based on the total weight of the preparation in encapsulated form. In this case, a content of 1 to 5% by weight, based on the total weight of the preparation, is preferred according to the invention. These quantities are based on the use concentration of butyl methoxydibenzoylmethane in the capsules (without the proportion by weight of PMMA).

If the formulation contains encapsulated 2,4-bis - {[4- (2-ethyl-hexyloxy) -2-hydroxy] -phenyl} -6- (4-methoxyphenyl) -1,3,5-triazine (INCI bis-ethylhexyloxyphenol Methoxyphenyl triazines), it is advantageous according to the invention if the preparation contains encapsulated 2,4-bis - {[4- (2-ethylhexyloxy) -2-hydroxy] phenyl} -6- (4-methoxyphenyl) -1,3, 5-triazine (INCI bis-ethylhexyloxyphenol methoxyphenyl triazines) in an amount of 0.1 to 30% by weight, based on the total weight of the preparation contains. According to the invention it is preferred if the encapsulated 2,4-bis - {[4- (2-ethyl-hexyloxy) -2-hydroxy] -phenyl} -6- (4-methoxyphenyl) -1,3,5-triazine ( INCI bis-ethylhexyloxyphenol methoxyphenyl triazine) in an amount of 1 to 20% by weight, based on the total weight of the preparation. These amounts are based on the total weight of bis-ethylhexyloxyphenol methoxyphenyl triazines and PMMA.

If the formulation contains encapsulated 2,4-bis - {[4- (2-ethyl-hexyloxy) -2-hydroxy] -phenyl} -6- (4-methoxyphenyl) -1,3,5-triazine (INCI bis-ethylhexyloxyphenol Methoxyphenyl triazines), it is advantageous according to the invention if the preparation is 2,4-bis - {[4- (2-ethyl-hexyloxy) -2-hydroxy] -phenyl} -6- (4-methoxyphenyl) -1,3 , 5-triazine (INCI bis-ethylhexyloxyphenol methoxyphenyl triazines) in an amount of 0.1 to 10% by weight, based on the total weight of the preparation in encapsulated form. In this case, a content of 1 to 5% by weight, based on the total weight of the preparation, is preferred according to the invention. These Quantities are based on the use concentration of bis-ethylhexyloxyphenol methoxyphenyl triazines in the capsules (without the proportion by weight of the PMMA).

It is advantageous according to the invention if the preparation contains perfumes in a total amount of from 0.1 to 5% by weight, based on the total weight of the preparation.

It is preferred according to the invention if the preparation contains perfumes in a total amount of from 0.1 to 4% by weight, based on the total weight of the preparation.

Embodiments of the present invention which are advantageous according to the invention are characterized in that the preparation contains, as perfume substances, one or more compounds selected from the group alpha-isomethylionone, benzyl alcohol, benzyl cinnamate, benzyl salicylate, citronellol, coumarin, eugenol, geraniol, hexyl cinnamal, linalool, limonene.

Moreover, it is particularly preferred according to the invention if the preparation is free of lyral.

Embodiments of the present invention which are advantageous according to the invention are characterized in that the preparation comprises ethylhexylglycerol, propylene glycol, butylene glycol, 2-methylpropane-1,3-diol, 1,2-pentanediol, 1,2-hexanediol, 1,2-octanediol and / or 1 Contains 2-decanediol.

Furthermore, it is advantageous according to the invention if the preparation additionally contains one or more unencapsulated UV filters which are selected from the group of the compounds 2-phenylbenzimidazole-5-sulphonic acid and / or salts thereof; Phenylene-1,4-bis- (2-benzimidazyl) -3,3'-5,5'-tetrasulfonsäuresalze; 1,4-di (2-oxo-10-sulfo-3-bomylidenemethyl) benzene and its salts; 4- (2-oxo-3-bornylidenemethyl) benzenesulfonic acid; 2-methyl-5- (2-oxo-3-bornylidenemethyl) sulfonic acid salts; 2,2'-methylene-bis- (6- (2H-benzotriazol-2-yl) -4- (1,1,3,3-tetramethylbutyl) -phenol); 2- (2H-benzotriazol-2-yl) -4-methyl-6- [2-methyl-3- [1,3,3,3-tetramethyl-1 - [(trimethylsilyl) oxy] disiloxanyl] propyl] phenol ; 3- (4-methylbenzylidene) camphor; 3-benzylidenecamphor; ethylhexyl salicylate; Terephthalidendicamphersulfonsäure; 2-ethylhexyl-2-cyano-3,3-diphenylacrylate; 4- (dimethylamino) benzoic acid (2-ethylhexyl) ester; 4- (dimethylamino) benzoic acid amyl ester; 4-Methoxybenzalmalon-säuredi (2-ethylhexyl) ester; 4-methoxycinnamate (2-ethylhexyl) ester; Isoamyl 4-methoxycinnamate; 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone; 2,2'-dihydroxy-4-methoxybenzophenone; homomenthyl; 2-ethylhexyl 2-hydroxybenzoate; dimethicodiethylbenzalmalonate; 3- (4- (2,2-bisethoxycarbonylvinyl) phenoxy) propenyl) methoxysiloxane / dimethylsiloxane copolymer; 4- (tert-butyl) -4'-methoxydibenzoylmethane; 2- (4'-diethylamino-2'-hydroxybenzoyl) benzoate; Dioctylbutylamidotriazone (INCI: diethylhexyl-butamidotriazone); 2,4-bis- [5-1 (dimethylpropyl) benzoxazol-2-yl- (4-phenyl) -imino] -6- (2-ethylhexyl) -imino-1,3,5-triazine having the (CAS No 288254-16-0); 2,4-bis - {[4- (2-ethylhexyloxy) -2-hydroxy] -phenyl} -6- (4-methoxyphenyl) -1,3,5-triazine (INCI: bis-ethylhexyloxyphenol methoxyphenyl triazine); 4,4 ', 4 "- (1,3,5-triazine-2,4,6-triyltriimino) tris-benzoic acid tris (2-ethylhexyl ester) (also: 2,4,6-tris [anilino - (p-carbo-2'-ethyl-1'-hexyloxy)] - 1,3,5-triazine (INCI: ethylhexyl triazone); 2,4,6-tribiphenyl-4-yl-1,3,5- triazine; merocyanines; titanium dioxide; zinc oxide.

It is particularly preferred according to the invention if the preparation is free of 3- (4-methylbenzylidene) camphor and 2-hydroxy-4-methoxybenzophenone (oxybenzone).

In addition, there is the possibility that the formulation contains non-encapsulated 4- (tert-butyl) -4'-methoxydibenzoylmethane (INCI butyl methoxydibenzoylmethane) and / or 2,4-bis - {[4- (2-ethylhexyloxy) -2- hydroxy] -phenyl} -6- (4-methoxyphenyl) -1,3,5-triazine (INCI bis-ethylhexyloxyphenol methoxyphenyl triazine).

Embodiments which are advantageous according to the invention are characterized in that the preparation is in the form of an oil-in-water emulsion (O / W emulsion).

In such a case, it is preferred according to the invention if the preparation contains one or more emulsifiers selected from the group of the compounds glyceryl stearate citrate, cetearyl alcohol, sodium cetearyl sulfate + glyceryl stearate, cetearyl sulfosuccinate, sodium stearoyl glutamate, polyglyceryl-3-methyl glucose distearate, stearic acid, potassium cetyl phosphate.

It is advantageous for the purposes of the present invention if the preparation contains acrylate / C10-30 alkyl acrylate crosspolymer, xanthan gum, silica dimethyl silylates and / or tapioca starch.

It is erfindugnsgemäß also advantageous if the preparation one or more active ingredients selected from the group of the compounds magnolia extract, glycyrrhetinic acid, urea, arctiin, alpha-lipoic acid, folic acid, phytoene, D-biotin, coenzyme Q10, alpha-glucosylrutin, carnitine, carnosine , Caffeine, natural and / or synthetic isoflavonoids,

Glyceryl glucose, creatine, creatinine, taurine, tocopherol, tocopherol acetate, β-alanine and / or licochalcone A.

In addition, embodiments according to the invention are obtained if the preparation contains phenoxyethanol and / or methylparaben. It is preferred according to the invention, when the preparation is free of propyl and Butylparaben and 3-iodo-2-propinylbutylcarbamat.

Embodiments which are advantageous according to the invention are also characterized in that the preparation contains vinylpyrrolidone / hexadecene copolymer.

In such a case, it is preferred according to the invention if the preparation contains vinylpyrrolidone / hexadecene copolymer in an amount of 0.1 to 2% by weight, based on the total weight of the preparation.

It is inventively advantageous if the emulsion of the invention contains ethanol and / or glycerol.

If the emulsion contains ethanol, then a use concentration of 0.1 to 10% by weight, based on the total weight of the emulsion, is advantageous according to the invention.

If the emulsion contains glycerol, an application concentration of 0.1 to 10% by weight, based on the total weight of the emulsion, is advantageous according to the invention.

The oil phase of the preparation according to the invention may also contain other oil, fat and wax components, for example, polar oils from the group of lecithins or compounds such. Cocoglyceride, caprylic / capric triglyceride, olive oil, sunflower oil, jojoba oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, castor oil, wheat germ oil, grapeseed oil, thistle oil, evening primrose oil, macadamia nut oil and the like. Also compounds such as phenethyl benzoate, 2-phenylethyl benzoate, isopropyl lauroyl sarcosinate, phenyl trimethicone, cyclomethicone, dibutyl adipate, octyl palmitate, octyl cocoate, octyl isostearate, octyl dodecyl myristate, octyl dodecanol, cetearyl isononanoate, isopropyl myristate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, Isooctyl stearate, isononyl stearate, isononyl isononanoate, 2-ethylhexyl palmitate, 2-ethylhexyl laurate, 2-hexyldecyl stearate, 2-octyldodecyl palmitate, stearylheptanoate, oleyl oleate, oleyl erucate, erucyl oleate, erucyl erucate, tridecyl stearate, tridecyl trimellitate can be used.

Also advantageous according to the invention are z. As natural waxes of animal and vegetable origin, such as beeswax and other insect waxes and berry wax, shea butter and / or lanolin (wool wax).

Furthermore, the oil phase can be advantageously selected from the group of dialkyl ethers and dialkyl carbonates, advantageous z. B. dicaprylyl ether (Cetiol OE) and / or dicaprylyl, for example, that available under the trade name Cetiol CC in the company. Cognis.

It is furthermore advantageous to use the oil component (s) from the group of isoeicosane, neopentyl glycol diheptanoate, propylene glycol dicaprylate / dicaprate, caprylic / capric / diglyceryl succinate, butylene glycol dicaprylate / dicaprate, C _12-13 -alkyllactate, di-C _12-13 -alkyl tartrate, triisostearin, dipentaerythrityl Hexacaprylate / hexacaprate, propylene glycol monoisostearate, tricaprylin, dimethylisosorbide. It is particularly advantageous if the oil phase of the formulations according to the invention has a content of C _12-15 -alkyl benzoate.

Advantageous oil components are also z. Isopropyl palmitate, myristyl myristate, butyloctyl salicylate (for example that available under the trade name Hallbrite BHB from the company CP Hall), tridecyl salicylate (which is available under the trade name Cosmacol ESI from Sasol), C12-C15 alkyl salicylate (under the trade name Dermol NS available from Alzo), hexadecyl benzoate and butyl octyl benzoate, and mixtures thereof (Hallstar AB).

Any mixtures of such oil and wax components are also advantageous to use in the context of the present invention.

Furthermore, the oil phase can also advantageously contain non-polar oils, for example those which are selected from the group of branched and unbranched hydrocarbons and waxes, in particular mineral oil, Vaseline (petrolatum), paraffin oil, squalane and squalene, polyolefins, hydrogenated polyisobutenes, C13- 16 isoparaffin and isohexadecane. Among the polyolefins, polydecenes are the preferred substances.

It is preferred according to the invention for the preparation according to the invention to comprise dialkyl carbonate, dialkyl adipate and / or dialkyl glutarate.

It is particularly preferred according to the invention for the preparation according to the invention to contain di-n-octyl carbonate (INCI dicaprylyl carbonates) and / or di-n-butyl adipate (INCI dibutyl adipate).

In addition, the preparation according to the invention may contain the customary ingredients and be composed as a conventional preparation.

The preparation of the invention can be used particularly advantageously as a daily care product or sunscreen.

Comparative test

With the following experiment, the effect according to the invention could be exemplified:

a) In-vitro method for determining washability

As evidence of the improved leachability and reduced staining of the preparations of the invention, in vitro studies were carried out, the results of which are shown in Table 1.

Various sunscreen emulsions were examined for yellow spot formation over an in vitro application / wash cycle. White prewashed cotton monitors (100% cotton) were used. For this purpose, 25 mg of the test formulation were uniformly distributed on PMMA Schönberg plates (5.0 × 5.0 cm) and transferred directly to the test textile by means of pressure. Subsequently, the stained cotton samples were air-dried for 12 hours under laboratory conditions.

After drying, a colorimetric characterization of the resulting initial staining was carried out by measuring the degree of yellowness with the colorimeter spectro-color (Dr. Lange); Color measurement software: spectral-QC, version measurement geometry: d / 8 °, gloss component excluded, light source: D65 (corresponding to average daylight), calibration standard: LZM 268, measuring aperture: 10mm, sample background: backing paper without optical brightener, test climate: 21 ° C ( ± 1 ° C), 41% (± 4%) rel. Humidity.

The evaluation was based on the change in the b value from the CIE-Lab color measurement system. The B-axis characterizes the color impression yellow / blue in the CIE-Lab system, whereby positive b-values represent an increase in the yellow component. The higher the b value, the greater the yellow impression.

After the measuring process, the test cloths were washed separately in the dyeing and washing machine Linitest Plus (Atlas) (60 ° C, 1h, 20rpm, powder detergent (eg Ariel Compact powder detergent), 10 metal balls as additional charge) and then a rinsing process (20 ° C, 15min, tap water).

After drying for 12 h under laboratory conditions, a colorimetric characterization of the resulting staining was again carried out by measuring the color values as already described with the colorimeter spectro-color (Dr. Lange).

The CIE-Lab System or L * a * b * Color Space is a three-dimensional measurement space containing all perceptible colors. The color space is constructed on the basis of the counter color theory. One of the most important features of the L * a * b * color model is its device independence, that is, the colors are defined independently of the nature of their generation and rendering technique.

The corresponding EU directive is DIN EN ISO 11664-4 "Colorimetry - Part 4: CIE 1976 L * a * b * Color Space". The coordinates of the CIELAB plane are formed from the red / green value a and the yellow / blue value b. The brightness axis L is perpendicular to this plane. To DIN 6174 Write L, a, and b with * to distinguish against others, such as the "Hunter-Lab" system. Table 1: Comparison of formulation of test formulations and washing results

b) In-vitro method for determining sand adhesion

50 mg of the test emulsion was applied to PMMA Schönberg plates (5.0 × 5.0 cm) and evenly distributed with a fingerstall on the plate. Subsequently, the applied example formulation is dried for 15 min at room temperature. Thereafter, the weight of the dried plates was determined with an analytical balance. Subsequently, the plates were poured over with fine sea sand (1.07711.1000 sea sand reinst, Merck KGaA) in excess. By sliding the plates once on a dedicated slide (see below), loosely adhering sand with reproducible, uniform force was removed.

The adherent sand remaining on the plate was then determined by weighing. The sand adhesion can be determined with the following equation: Δ (adhesion) [mg] = m (plate with sand) [mg] - m (creamed plate) [mg]

The slip device is a triangular construction in which the width of the chute is 5 cm. The slide stands on the 13.5 cm long Ankathete. The Gegenkathete, which holds the hypotenuse used as a slide, has a length of 49 cm.

The experiments were repeated 10 times per formulation and the corresponding mean value was formed.

The sand resistance [mg / cm ² ] is the amount of sand that adheres less to the plate (eg sand resistance 1.0 mg / cm ² = There is 1.0 mg / cm ² less sand on the plate compared to the reference with unencapsulated UV filter). Table 2: Recipe comparison of the test formulations and sand resistance results

Examples

The following examples are intended to illustrate the present invention without limiting it. All amounts, proportions and percentages are, unless otherwise stated, based on the weight and the total amount or on the total weight of the preparations Table 3: Example formulations

QUOTES INCLUDE IN THE DESCRIPTION

This list of the documents listed by the applicant has been generated automatically and is included solely for the better information of the reader. The list is not part of the German patent or utility model application. The DPMA assumes no liability for any errors or omissions.

Cited patent literature

• WO 2006/046803 A1 [0015]

Cited non-patent literature

• DIN EN ISO 11664-4 [0061]
• DIN 6174 [0061]

Claims (17)

Contains cosmetic preparation a) a polymethyl methacrylate (PMMA) encapsulated UV filter and b) one or more perfumes. Cosmetic preparation according to claim 1, characterized in that encapsulated as encapsulated UV filter 4- (tert-butyl) -4'-methoxydibenzoylmethane (INCI butyl methoxydibenzoylmethane) and / or encapsulated 2,4-bis - {[4- (2 -ethyl-hexyloxy) -2-hydroxy] -phenyl} -6- (4-methoxyphenyl) -1,3,5-triazine (INCI bis-ethylhexyloxyphenol methoxyphenyl triazines). Cosmetic preparation according to one of the preceding claims, characterized in that the capsules of the PMMA encapsulated UV filters have an average size of 0.1 to 15 μm. Cosmetic preparation according to one of the preceding claims, characterized in that the preparation comprises encapsulated 4- (tert-butyl) -4'-methoxydibenzoylmethane (INCI butyl methoxydibenzoylmethane) in an amount of 0.1 to 20% by weight, based on the total weight of the preparation, contains. Cosmetic preparation according to one of the preceding claims, characterized in that the preparation comprises 4- (tert-butyl) -4'-methoxydibenzoylmethane (INCI butyl methoxydibenzoylmethane) in an amount of 0.1 to 5% by weight, based on the total weight of the Contains preparation in encapsulated form. Cosmetic preparation according to one of the preceding claims, characterized in that the preparation comprises encapsulated 2,4-bis - {[4- (2-ethyl-hexyloxy) -2-hydroxy] -phenyl} -6- (4-methoxyphenyl) -1 , 3,5-triazine (INCI bis-ethylhexyloxyphenol methoxyphenyl triazines) in an amount of 1 to 30% by weight, based on the total weight of the preparation contains. Cosmetic preparation according to one of the preceding claims, characterized in that the preparation contains 2,4-bis - {[4- (2-ethyl-hexyloxy) -2-hydroxy] -phenyl} -6- (4-methoxyphenyl) -1, 3,5-triazine (INCI bis-ethylhexyloxyphenol methoxyphenyl triazines) in an amount of 0.1 to 10% by weight, based on the total weight of the preparation in encapsulated form. Cosmetic preparation according to one of the preceding claims, characterized in that the preparation contains perfumes in a total amount of 0.1 to 5% by weight, based on the total weight of the preparation. Cosmetic preparation according to one of the preceding claims, characterized in that the preparation contains as perfuming one or more compounds selected from the group alpha-isomethylionone, benzyl alcohol, benzyl cinnamate, benzyl salicylate, citronellol, coumarin, eugenol, geraniol, Hexylcinnamal, linalool, limonene. Cosmetic preparation according to one of the preceding claims, characterized in that the preparation is free of lyral. Cosmetic preparation according to one of the preceding claims, characterized in that the preparation Ethylhexylglycerin, propylene glycol, butylene glycol, 2-methylpropane-1,3-diol, 1,2-pentanediol, 1,2-hexanediol, 1,2-octanediol and / or Contains 1,2-decanediol. Cosmetic preparation according to one of the preceding claims, characterized in that the preparation additionally contains one or more non-encapsulated UV filters, which are selected from the group of the compounds 2-phenylbenzimidazole-5-sulfonic acid and / or salts thereof; Phenylene-1,4-bis- (2-benzimidazyl) -3,3'-5,5'-tetrasulfonsäuresalze; 1,4-di (2-oxo-10-sulfo-3-bomylidenemethyl) benzene and its salts; 4- (2-oxo-3-bornylidenemethyl) benzenesulfonic acid; 2-methyl-5- (2-oxo-3-bornylidenemethyl) sulfonic acid salts; 2,2'-methylene-bis- (6- (2H-benzotriazol-2-yl) -4- (1,1,3,3-tetramethylbutyl) -phenol); 2- (2H-benzotriazol-2-yl) -4-methyl-6- [2-methyl-3- [1,3,3,3-tetramethyl-1 - [(trimethylsilyl) oxy] disiloxanyl] propyl] phenol ; 3- (4-methylbenzylidene) camphor; 3-benzylidenecamphor; ethylhexyl salicylate; Terephthalidendicamphersulfonsäure; 2-ethylhexyl-2-cyano-3,3-diphenylacrylate; 4- (dimethylamino) benzoic acid (2-ethylhexyl) ester; 4- (dimethylamino) benzoesäureamylester; 4-Methoxybenzalmalon-säuredi (2-ethylhexyl) ester; 4-methoxycinnamate (2-ethylhexyl) ester; Isoamyl 4-methoxycinnamate; 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4- methoxy-4'-methylbenzophenone;2,2'-dihydroxy-4-methoxybenzophenone;homomenthyl; 2-ethylhexyl 2-hydroxybenzoate; dimethicodiethylbenzalmalonate; 3- (4- (2,2-bisethoxycarbonylvinyl) phenoxy) propenyl) methoxysiloxane / dimethylsiloxane copolymer; 4- (tert-butyl) -4'-methoxydibenzoylmethane; 2- (4'-diethylamino-2'-hydroxybenzoyl) benzoate; Dioctylbutylamidotriazone (INCI: diethylhexyl-butamidotriazone); 2,4-bis- [5-1 (dimethylpropyl) benzoxazol-2-yl- (4-phenyl) -imino] -6- (2-ethylhexyl) -imino-1,3,5-triazine having the (CAS No 288254-16-0); 2,4-bis - {[4- (2-ethylhexyloxy) -2-hydroxy] -phenyl} -6- (4-methoxyphenyl) -1,3,5-triazine (INCI: bis-ethylhexyloxyphenol methoxyphenyl triazine); 4,4 ', 4 "- (1,3,5-triazine-2,4,6-triyltriimino) tris-benzoic acid tris (2-ethylhexyl ester) (also: 2,4,6-tris [anilino - (p-carbo-2'-ethyl-1'-hexyloxy)] - 1,3,5-triazine (INCI: ethylhexyl triazone); 2,4,6-tribiphenyl-4-yl-1,3,5- triazine; merocyanines; titanium dioxide; zinc oxide. Cosmetic preparation according to one of the preceding claims, characterized in that the formulation contains non-encapsulated 4- (tert-butyl) -4'-methoxydibenzoylmethane (INCI butyl methoxydibenzoylmethane) and / or 2,4-bis - {[4- (2-ethylhexyloxy ) -2-hydroxy] -phenyl} -6- (4-methoxyphenyl) -1,3,5-triazine (INCI bis-ethylhexyloxyphenol methoxyphenyl triazine). Cosmetic preparation according to one of the preceding claims, characterized in that the preparation is in the form of an oil-in-water emulsion (O / W emulsion). Cosmetic preparation according to one of the preceding claims, characterized in that the preparation contains acrylate / C10-30 alkyl acrylate crosspolymer, xanthan gum, silica dimethyl silylates and / or tapioca starch. Cosmetic preparation according to one of the preceding claims, characterized in that the preparation one or more active ingredients selected from the group of the compounds magnolia extract, glycyrrhetinic acid, urea, arctiin, alpha-lipoic acid, folic acid, phytoene, D-biotin, coenzyme Q10, alpha-glucosylrutin , Carnitine, carnosine, caffeine, natural and / or synthetic isoflavonoids, glyceryl glucose, creatine, creatinine, taurine, tocopherol, tocopherol acetate, β-alanine and / or licochalcone A. Cosmetic preparation according to one of the preceding claims, characterized in that the preparation contains phenoxyethanol and / or methylparaben.